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Introduction: Biomarkers of brain damage and head injury are potentially useful tools in the management of
afflicted patients. Particularly S100B has received much attention and has been adapted into clinical guidelines. Alcohol
intoxication and higher age (65 years and over) have been used as risk factors for serious complications following head
injury. The effect of these factors on S100B levels has not been fully established in a relevant patient cohort.
Methods: We prospectively included 621 adult patients with mild traumatic brain injury (TBI) and S100B sampling. Mild
TBI was defined as Glasgow Come Scale 14–15 with loss of consciousness and/or amnesia, but without high-risk
factors for intracranial complications. These patients would normally require CT scanning according to local and most
international guidelines. S100B was sampled within 3 hours following trauma.
Results: 280 patients (45%) were intoxicated by alcohol. Alcohol intoxication had no effect on S100B levels (p = 0.65)
and the performance of S100B remained unchanged in these patients. 115 patients (22%) were 65 years or older with
elevated S100B levels being more common in this group compared to patients under 65 (p = 0.029). Although the
sensitivity of S100B was unchanged in older patients, the specificity was poorer.
Conclusion: S100B can be used reliably in mild TBI patients with alcohol intoxication. The clinically utility of S100B in
older patients may be limited by very poor specificity leading to only a small decrease in CT scanning.Introduction
Biochemical markers are used as screening and diagnostic
tools in many clinical scenarios. Recently, biomarkers for
diagnosis and prognosis of brain injury have developed [1].
These may allow faster and more accurate management of
brain disease, similarly to biomarkers used in other organ
systems. Traumatic brain injury (TBI) is a leading cause of
death, especially in younger individuals [2]. Management
usually involves computed tomography of the brain to
detect lesions that may need neurosurgical or medical
intervention. However, most of there injuries are not
serious in nature, often called mild TBI or minor
head injury. Serious complications following mild TBI
are rare, with approximately 5% displaying traumatic
CT pathology and less than 1% needing specific* Correspondence: dr.johan.unden@gmail.com
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distribution, and reproduction in any mediumintervention [3,4]. Despite this, CT is recommended in
these patients due to the seriousness of the complications
[5-7]. Attempts to reduce CT use have been based upon
aspects of patient history and clinical examination.
However, these may be inaccurate in any patients,
especially in those with head trauma or brain injury.
An objective biomarker would therefore we welcomed
in the management of these patients.
S100B is a small calcium-binding protein weighing
approximately 21 kDa, predominantly expressed by glia
cells. When brain tissues and/or the blood brain barrier
(BBB) are damaged, S100B is released and can be
detected in the peripheral blood. Many studies have
shown the potential of S100B as a biomarker in brain
injuries [8-10]. In particular, the potential of S100B to
reduce unnecessary CT scans following mild TBI has
received considerable attention. Recently, international
guidelines have been published including S100B as a
management option [11].tral Ltd. This is an Open Access article distributed under the terms of the
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[12]. Although some studies have shown little effect of
alcohol on S100B levels [12], others have shown conflicting
results [13]. This aspect is important if the biomarker is to
function effectively in this population. False high S100B
due to alcohol intoxication would limit the CT-reducing
ability of the biomarker.
Children have higher levels of S100B than adults [14].
However, levels of S100B in elderly patients following
mild TBI have not been investigated. Since older age
(most often defined as over 65 years of age) is often
included as a risk factor for complications after TBI
[15,16], this aspect is also of importance.
The aim of this study is to investigate the relationship
of older age and alcohol intoxication to serum S100B
levels following mild TBI in a large prospective cohort.
Methods
Study setting and cohort population
We undertook a prospective study in Halmstad Regional
hospital, Sweden, from June 2008 to December 2012. Our
hospital is a level II trauma centre with 24-hour emergency
care, anesthesiology, radiology, surgery and intensive care.
Approximately 6 months prior to the study, local
guidelines for management of mild TBI, including
S100B sampling, were introduced into clinical practice.
We consecutively enrolled all adult patients with mild
TBI and subsequent S100B sampling. Inclusion criteria
were; adult patients with trauma to the head with GCS
14–15 during examination and loss of consciousness <
5 minutes or amnesia. Exclusion criteria were; age less
than 18 years, focal neurological deficit, therapeutic
anticoagulation or haemophilia, radiographically demon-
strated skull fracture, clinical signs of depressed skull
fracture or skull base fracture, posttraumatic seizure,
shunt-treated hydrocephalus, multiple organ trauma and
patients where serum sampling for S100B was taken
more than 3 hours post-injury.
Patient age at time of trauma and alcohol intoxication
(yes/no based upon patient history and examination)
was prospectively documented. Determination of blood
alcohol levels was determined based upon the discretion
of the treating physician. The age limit of 65 years or
older was the pre-determined cut-off for analysis based
upon published management rules [11,16].
The study was approved by the regional ethical board
(approval number 19/2007).
Blood sampling and biochemical analysis
A 5 ml blood sample was drawn from patient’s cubital vein
in the ED. Samples were analyzed with the fully automated
Elecsys® S100 (Roche AB) at the Clinical Chemistry
Department of Halmstad Regional hospital, Sweden. Roche
AB report a range between 0.005 μg/L and 39 μg/L and awithin-series coefficient of variance of <2.1%. Based on the
available evidence at this time, we chose a cut-off level for
normal levels of less than 0.10 μg/L and a window of
sampling of 3 hours from the time of the accident
[17,18]. Lab results were available to treating physicians
within 1 hour after sampling.
CT examinations
Cranial CT scans were performed with a GE VCT
Ligthspeed 64 multislice detector with a 0,625/0,625 mm,
0,5 seconds rotation time and pitch of 0,531:1. 10 mm
thick slices were used as part of the standard CT protocol
for these patients. CT scans are always analysed by a board
certified radiologist and confirmed by a consultant radiolo-
gist. Since S100B was used clinically, radiologists were not
blinded to S100B results. A CT scan was considered posi-
tive if any sings of cranial (skull fracture) or intracranial
pathology (hematoma, air or contusion) were present.
Follow-up
Patients were followed up after 3 months post-trauma
by questionnaire. This contained information regarding
clinical symptoms suggestive of intracranial complications
and included additional (new) CT scans and/or exposure
to the health care system. Patients who were lost to
follow-up were checked by examination of medical
records and national mortality databases for signs of
intracranial complications or death.
Statistic analysis
Data was registered on an Excel® file. The difference in
S100B levels between age groups and intoxicated/sober
patients were calculated with a Mann–Whitney test. A
non-parametric test was chosen due to a skewed distri-
bution of data.
Results
Between June 2008 and December 2012, we enrolled 621
patients with mild TBI and S100B levels. 351 patients
had CT scans as part of their management (322 with
S100B levels equal to or higher than 0.10 μg/L and 29
patients with S100 levels lower than 0.10 μg/L). 513
(83%) of patients had successful and complete follow-up
including 242 (90%) of the 270 patients not receiving an
initial CT. No patients showed any new signs of intracra-
nial complications. A total of 29 patients had cranial CT
pathology but only 26 (4.7%) of these showed traumatic
abnormalities (isolated skull fracture n = 3, cerebral contu-
sions n = 9, acute subdural hematoma n = 3, intracranial
air n = 1, combinations of traumatic intracranial findings
n = 10). The remaining 3 patients had non-traumatic
findings unrelated to the injury.
280 patients (45%) were intoxicated by alcohol and a
blood alcohol level was determined in 197 patients. All
Figure 1 Bar graph showing the relationship between age and S100B levels.
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clinically suspected of intoxication and all had measureable
levels. 115 patients (19%) of the total cohort were 65 years
or older.
180 patients (29%) had a S100B level lower than
0.10 μg/L: 171 of these (95%) were younger than 65 years
and only 9 patients (5%) were older or equal than
65 years of age. Figure 1 shows a bar graph of age and
S100B levels in the study population. 441 patients (71%)
showed a S100B level higher or equal to 0.10 μg/L: 335
(76%) of these were younger than 65 years old and 106
patients (24%) were older or equal than 65 years old.
The difference in S100B levels between the age groups
was significant (p = 0.029), see Table 1. A scatter plot of
age verses S100B levels is shown in Figure 2.
Table shows the number of patients (and interquartile
range in brackets) with S100B levels above and below
0.10 μg/L and the number of patients above or below
65 years of age and with or without alcohol intoxication.
The difference in S100B levels between patients 65
and over with patients under 65 years was significant
(p = 0.029) and the difference between intoxication and no
intoxication was not significant (p = 0.65).
206 of the 280 patients (74%) who were intoxicated by
alcohol had a S100B level higher or equal to 0.10 μg/L.Table 1 S100B levels in 621 patients with mild TBI
S100b < 0.10 μg/L Med
<65 years 171 patients
(0
≥65 years 9 patients
(0
No Alcohol intoxication 106 patients
(0
Alcohol intoxication 74 patients
(0235 of the 338 (70%) patients without alcohol intoxication
had elevated S100B levels. There was no statistical differ-
ence in S100B levels between those patients with and
without intoxication (p = 0.65), see Table 1. For the 197
patients where serum ethanol levels were determined, a
scatterplot was created, see Figure 3. 10 patients were both
65 years or older and intoxicated by alcohol.
S100B had a sensitivity of 100% and a specificity of 30%
for CT findings in the entire population. The specificity
increased to 35% if only patients younger than 65 years
were considered. The positive likelihood ratio that a
S100B level higher or equal to 0.10 μg/L would predict a
pathological CT was 1.44 for the entire population while
it increased to 1.54 if we considered only patients younger
than 65 years of age.
Discussion
The initial management of mild TBI is still under debate.
Several guidelines and decision rules, derived from
different cohorts from different countries, have been
published and are currently used clinically [11,15,16,19].
The introduction of S100B into clinical practice has
been shown to improve the management of mild
TBI [20] with a reduction of CT scans following
these injuries. This has the potential to reduce costsian S100b S100b ≥ 0.10 μg/L Median S100b
μg/L μg/L
0.07 335 patients 0.19
.03-0.09) (0.10-4.51)
0.07 106 patients 0.23
.04-0.09) (0.10-6.75)
0.07 235 patients 0.20
.03-0.09) (0.10-6.75)
0.07 206 patients 0.20
.03-0.09) (0.10-4.51)
Figure 2 Scatter plot showing S100B levels verses age in patients following mild TBI. Spearman’s rho 0,295, p = 0,000.
Calcagnile et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2013, 21:52 Page 4 of 6
http://www.sjtrem.com/content/21/1/52and potential radiation dosages to patients with head
injury.
New, updated international guidelines, including blood
sampling for S100B, are presently being implemented in
Scandinavia [11]. These guidelines recommend S100B sam-
pling in adult patients with loss of consciousness and/or
repeated (more than one episode) vomiting if other risk
factors are absent. One such risk factor is older age (65 yearsFigure 3 Scatter plot showing S100B levels verses serum ethanol leveor older) in combination with anti-thrombocyte medica-
tion. As many elderly patients take these medications, the
majority of these patients will have this risk factor and not
be eligible for S100B sampling. Based upon the results of
this study, this approach seems reasonable. Even if the sen-
sitivity of S100B for CT findings was still 100% in elderly
patients, the specificity was worse. In practice, this results
in a smaller potential reduction in CT scanning after mildls in patients following mild TBI. Spearman’s rho 0,092, p = 0,249.
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reason for this observation is unclear. One may speculate
that the higher S100B levels observed are merely a
reflection of the increased risk of brain injury these patients
have following brain trauma. If this is the case, S100B levels
may still correctly classify these patients as high risk mild
TBI indicating the necessity of a CT scan. Also, older
patients often have concurrent chronic disease and may also
have neurological disease such as Alzheimer’s disease or
Parkinson’s disease. In the present study, non-neurological
disease was not registered and the prevalence of neurode-
generative disease was too low to perform any meaningful
analysis. It may also be argued that the cut-off for S100B
should be higher in older patients. This was, however,
not an endpoint of this study. Higher cut-off levels
have been shown to be more specific in previous
studies [21]. However, the large body of evidence and
current clinical practice is focused on the 0.10 μg/L level
and is seems reasonable to primarily consider this cut-off
although to ensure maximal sensitivity in clinical practice.
These issues should be confirmed in future studies.
We found no affect of alcohol on S100B levels,
irrespective of whether alcohol intoxication was derived
from patient history and clinical examination or from
objective blood ethanol levels. This confirms previous
observations from another cohort [12] but is somewhat in
contrast to other reports [13]. Different methods of S100B
analysis may have influenced these conflicting results [22].
The results from this study are based upon a much larger
cohort than the previous studies and consider a pragmatic
and clinically relevant patient material. This observation is
important considering the frequency of alcohol intoxication
in these patients. Indeed, in this study, 45% of patients were
intoxicated by alcohol.
Considering these results, S100B can be used freely in
mild TBI patients with alcohol intoxication. This is naturally
welcomed, due to the difficulties of assessing patient history,
performing adequate and reliable clinical examination and
obtaining a cranial CT scan of intoxicated patients. Al-
though S100B shows a 100% sensitivity for CT findings after
mild TBI in all age groups, the performance of the bio-
marker, specifically the ability of S100B to decrease
unnecessary CT scans, will likely be reduced in elderly
(65 years or older) patients. Although this is in accordance
to recent guidelines [11], this should also be considered in
other scenarios. The health economic implications of S100B
use in this patient group remains to be shown.
Conclusion
In patients with mild TBI, S100B is unaffected by alcohol
intoxication and may be used effectively in this patient
group. Patients aged 65 years and older had higher S100B
levels and the overall ability of S100B to reduce CT scans
in the elderly may be impaired.Competing interests
JU has in previous studies (unconnected with the current study) received
S100B analysis kits from Roche AB, Sweden and Diasorin AB, Sweden. JU has
previously lectured for Roche AB, Sweden. AH, OC and MC did not have any
competing interests.Authors’ contributions
JU and OC conceived the study. JU and OC acquired data. JU, AH, MC and
JU did data analysis. JU and OC drafted the paper with input from AH and
MC. All authors read and approved the final manuscript.
Author details
1Department of Pediatric Medicine, Hallands Hospital, Halmstad 30185,
Sweden. 2Department of Research and Development, Hallands Hospital,
Halmstad 30185, Sweden. 3Department of Anaesthesia and Intensive Care
and Institute of Clinical Sciences Malmö, Lund University, Hallands Hospital,
Halmstad 30185, Sweden. 4Department of Intensive Care and Perioperative
Medicine and Institute of Clinical Sciences Malmö, Lund University, Skanes
University Hospital, Malmo 20502, Sweden.
Received: 15 May 2013 Accepted: 3 July 2013
Published: 6 July 2013References
1. Ingebrigtsen T, Romner B, Kongstad P, Langbakk B: Increased serum
concentrations of protein S-100 after minor head injury: a biochemical
serum marker with prognostic value? J Neurol Neurosurg Psychiatry 1995,
59(1):103–104.
2. Soreide K, Kruger AJ, Vardal AL, Ellingsen CL, Soreide E, Lossius HM:
Epidemiology and contemporary patterns of trauma deaths: changing
place, similar pace, older face. World J Surg 2007, 31(11):2092–2103.
3. Morton MJ, Korley FK: Head computed tomography use in the
emergency department for mild traumatic brain injury: integrating
evidence into practice for the resident physician. Ann Emerg Med 2012,
60(3):361–367.
4. Af Geijerstam JL, Britton M: Mild head injury - mortality and complication
rate: meta-analysis of findings in a systematic literature review. Acta
Neurochir (Wien) 2003, 145(10):843–850. discussion 850.
5. Stein SC: Indications for computed tomography after minor head injury.
N Engl J Med 2000, 343(21):1570. author reply 1571.
6. Stein SC: Mild head injury. J Neurosurg 2005, 102(1):183–184. author
reply 185.
7. Ingebrigtsen T, Romner B, Kock-Jensen C: Scandinavian guidelines for
initial management of minimal, mild, and moderate head injuries. The
Scandinavian Neurotrauma Committee. J Trauma 2000, 48(4):760–766.
8. Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H: GFAP
versus S100B in serum after traumatic brain injury: relationship to brain
damage and outcome. J Neurotrauma 2004, 21(11):1553–1561.
9. Foerch C, Wunderlich MT, Dvorak F, Humpich M, Kahles T, Goertler M,
Alvarez-Sabin J, Wallesch CW, Molina CA, Steinmetz H, et al: Elevated serum
S100B levels indicate a higher risk of hemorrhagic transformation after
thrombolytic therapy in acute stroke. Stroke 2007, 38(9):2491–2495.
10. Mussack T, Biberthaler P, Wiedemann E, Kanz KG, Englert A,
Gippner-Steppert C, Jochum M: S-100b as a screening marker of the
severity of minor head trauma (MHT)–a pilot study. Acta Neurochir Suppl
2000, 76:393–396.
11. Unden J, Ingebrigtsen T, Romner B: Scandinavian guidelines for initial
management of minimal, mild and moderate head injuries in adults: an
evidence and consensus-based update. BMC Med 2013, 11:50.
12. Mussack T, Biberthaler P, Kanz KG, Heckl U, Gruber R, Linsenmaier U,
Mutschler W, Jochum M: Immediate S-100B and neuron-specific enolase
plasma measurements for rapid evaluation of primary brain damage in
alcohol-intoxicated, minor head-injured patients. Shock 2002,
18(5):395–400.
13. Lange RT, Iverson GL, Brubacher JR: Clinical utility of the protein S100B to
evaluate traumatic brain injury in the presence of acute alcohol
intoxication. J Head Trauma Rehabil 2012, 27(2):123–134.
14. Astrand R, Romner B, Lanke J, Unden J: Reference values for venous and
capillary S100B in children. Clin Chim Acta 2011, 412(23–24):2190–2193.
Calcagnile et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2013, 21:52 Page 6 of 6
http://www.sjtrem.com/content/21/1/5215. Haydel MJ, Preston CA, Mills TJ, Luber S, Blaudeau E, DeBlieux PM:
Indications for computed tomography in patients with minor head
injury. N Engl J Med 2000, 343(2):100–105.
16. Stiell IG, Wells GA, Vandemheen K, Clement C, Lesiuk H, Laupacis A,
McKnight RD, Verbeek R, Brison R, Cass D, et al: The Canadian CT head rule
for patients with minor head injury. Lancet 2001, 357(9266):1391–1396.
17. Biberthaler P, Linsenmeier U, Pfeifer KJ, Kroetz M, Mussack T, Kanz KG,
Hoecherl EF, Jonas F, Marzi I, Leucht P, et al: Serum S-100B concentration
provides additional information fot the indication of computed
tomography in patients after minor head injury: a prospective
multicenter study. Shock 2006, 25(5):446–453.
18. Muller K, Townend W, Biasca N, Unden J, Waterloo K, Romner B,
Ingebrigtsen T: S100B serum level predicts computed tomography
findings after minor head injury. J Trauma 2007, 62(6):1452–1456.
19. Smits M, Dippel DW, Steyerberg EW, de Haan GG, Dekker HM, Vos PE, Kool
DR, Nederkoorn PJ, Hofman PA, Twijnstra A, et al: Predicting intracranial
traumatic findings on computed tomography in patients with minor
head injury: the CHIP prediction rule. Ann Intern Med 2007,
146(6):397–405.
20. Calcagnile O, Unden L, Unden J: Clinical validation of S100B use in
management of mild head injury. BMC Emerg Med 2012, 12:13.
21. Cervellin G, Benatti M, Carbucicchio A, Mattei L, Cerasti D, Aloe R, Lippi G:
Serum levels of protein S100B predict intracranial lesions in mild head
injury. Clin Biochem 2012, 45(6):408–411.
22. Muller K, Elverland A, Romner B, Waterloo K, Langbakk B, Unden J,
Ingebrigtsen T: Analysis of protein S-100B in serum: a methodological
study. Clin Chem Lab Med 2006, 44(9):1111–1114.
doi:10.1186/1757-7241-21-52
Cite this article as: Calcagnile et al.: S100B levels are affected by older
age but not by alcohol intoxication following mild traumatic brain
injury. Scandinavian Journal of Trauma, Resuscitation and Emergency
Medicine 2013 21:52.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
